{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:22:21Z","timestamp":1787678541624,"version":"build-2784847793"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102578","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:31:14Z","timestamp":1748629874000},"page":"102578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Can we cure Sjogren\u2019s disease? Unmet needs and raising questions in the era of Precision medicine"],"prefix":"10.1016","volume":"95","author":[{"given":"Loukas","family":"Chatzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas V","family":"Goules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102578_sbref1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41584-023-01036-x","article-title":"25 years of biologic DMARDs in rheumatology","volume":"19","author":"Feldmann","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib2","first-page":"27","article-title":"Limited efficacy of targeted treatments in Sj\u00f6gren's syndrome: why?","volume":"36 Supp 112","author":"Tzioufas","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism Classification Criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102578_bib5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","article-title":"Current and future therapies for primary Sj\u00f6gren syndrome","volume":"17","author":"Seror","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib6","first-page":"283","article-title":"Ten years of the ESSDAI: is it fit for purpose?","volume":"38 126","author":"de Wolff","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_sbref7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sj\u00f6gren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2025.102578_bib8","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren's syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102578_bib9","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren's Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_sbref10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the pathophysiology and treatment of primary Sj\u00f6gren syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_sbref11","article-title":"Genome-wide association study identifies Sj\u00f6gren's risk loci with functional implications in immune and glandular cells","volume":"13","author":"Khatri","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102578_bib12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/ng.2779","article-title":"A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sj\u00f6gren's syndrome at 7q11.23","volume":"45","author":"Li","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102578_bib13","article-title":"A high polygenic risk score is associated with SSA\/SSB antibody positivity and early onset in primary Sj\u00f6gren's disease","author":"Fugmann","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102578_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1246818","article-title":"Current and emerging evidence for Toll-like receptor activation in Sj\u00f6gren's syndrome","volume":"2018","author":"Kiripolsky","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.coi.2025.102578_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jaut.2010.06.010","article-title":"Salivary epithelial cells from Sjogren's syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation","volume":"35","author":"Manoussakis","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102578_bib16","first-page":"693","article-title":"c-myc mRNA expression in minor salivary glands of patients with Sj\u00f6gren's syndrome","volume":"19","author":"Skopouli","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/34.4.326","article-title":"Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sj\u00f6gren's syndrome","volume":"34","author":"Boumba","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","article-title":"Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/clin.1994.1123","article-title":"Sj\u00f6gren's syndrome: autoimmune epithelitis","volume":"72","author":"Moutsopoulos","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.coi.2025.102578_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/biom11020251","article-title":"The role of interferons in the pathogenesis of Sj\u00f6gren's syndrome and future therapeutic perspectives","volume":"11","author":"Del Papa","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.coi.2025.102578_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sj\u00f6gren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102578_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102578_bib23","first-page":"245","article-title":"Type-III interferons in Sj\u00f6gren's syndrome","volume":"38 Suppl 126","author":"Apostolou","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaut.2008.04.008","article-title":"B cell apotopes of the 60-kDa Ro\/SSA and La\/SSB autoantigens","volume":"31","author":"Reed","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102578_bib25","first-page":"222","article-title":"Blocking T cell co-stimulation in primary Sj\u00f6gren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers","volume":"38 Suppl 126","author":"Pontarini","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/BOR.0000000000000473","article-title":"Current views on the pathogenesis of Sj\u00f6gren's syndrome","volume":"30","author":"Pontarini","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib27","first-page":"2336","article-title":"Pathogenesis of Sj\u00f6gren's disease: one year in review 2024","volume":"42","author":"Baldini","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.semarthrit.2012.07.003","article-title":"The role of ectopic germinal centers in the immunopathology of primary Sj\u00f6gren's syndrome: a systematic review","volume":"42","author":"Risselada","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102578_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sj\u00f6gren's syndrome: predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102578_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/path.6039","article-title":"Lymphoma-associated mutations in autoreactive memory B cells of patients with Sj\u00f6gren's syndrome","volume":"259","author":"Bende","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.coi.2025.102578_bib31","doi-asserted-by":"crossref","first-page":"E579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"CMAJ: Canadian Medical Association journal = journal de l\u2032Association medicale canadienne"},{"key":"10.1016\/j.coi.2025.102578_bib32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.csbj.2022.01.002","article-title":"Addressing the clinical unmet needs in primary Sj\u00f6gren's syndrome through the sharing, harmonization and federated analysis of 21 European cohorts","volume":"20","author":"Pezoulas","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.coi.2025.102578_bib33","first-page":"2507","article-title":"The clinical phenotype of isolated ocular or oral dryness in Sj\u00f6gren's disease","volume":"42","author":"Chatzis","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594096","article-title":"Primary Sj\u00f6gren's syndrome of early and late onset: distinct clinical phenotypes and lymphoma development","volume":"11","author":"Goules","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102578_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.55563\/clinexprheumatol\/47a4kr","article-title":"Combined seronegativity in Sj\u00f6gren's syndrome","volume":"39","author":"Chatzis","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib36","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2665-9913(24)00183-8","article-title":"Identification and evolution of predictors of Sj\u00f6gren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study","volume":"6","author":"Goules","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102648","article-title":"A biomarker for lymphoma development in Sjogren's syndrome: salivary gland focus score","volume":"121","author":"Chatzis","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102578_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102578_bib39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sj\u00f6gren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"Jama"},{"key":"10.1016\/j.coi.2025.102578_bib40","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coi.2025.102578_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.coi.2025.102578_sbref42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/rheumatology\/keae152","article-title":"British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease","volume":"64","author":"Price","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102578_bib43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijporl.2018.07.002","article-title":"Juvenile recurrent parotitis: a systematic review of treatment studies","volume":"112","author":"Garavello","year":"2018","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.coi.2025.102578_bib44","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102578_bib45","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome--a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102578_bib47","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102578_bib48","first-page":"6","article-title":"Effects of rituximab therapy on quality of life in patients with primary Sj\u00f6gren's syndrome","volume":"29","author":"Devauchelle-Pensec","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib49","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib50","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102578_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102578_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2025.102578_bib53","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib54","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102578_sbref55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102578_sbref56","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102578_bib57","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_othref0005","doi-asserted-by":"crossref","unstructured":"Gottenberg JE, Sivils K, Campbell K, Idokogi J, Lo KH, Liva S, et al.: LBA0010\u2005Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren\u2019s Disease: Results From a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS). 2024;83(Suppl 1):240\u2013","DOI":"10.1136\/annrheumdis-2024-eular.LBA90"},{"key":"10.1016\/j.coi.2025.102578_bib59","unstructured":"ClinicalTrials.gov UNLoM. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06312020?term=Sj%C3%B6gren%27s%20Syndrome&sort=StudyFirstPostDate&limit=25&page=2&rank=47\u3009."},{"key":"10.1016\/j.coi.2025.102578_sbref58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102578_sbref59","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102578_bib62","unstructured":"ClinicalTrials.gov UNLoM. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06862284?term=Sj%C3%B6gren%27s%20Syndrome&sort=StudyFirstPostDate&limit=25&page=1&rank=3\u3009."},{"key":"10.1016\/j.coi.2025.102578_bib63","unstructured":"ClinicalTrials.gov UNLoM. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05383677?term=sjogren%27s%20syndrome%20anifrolumab&rank=1\u3009."},{"key":"10.1016\/j.coi.2025.102578_bib64","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_sbref61","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23472-7","article-title":"A new molecular classification to drive precision treatment strategies in primary Sj\u00f6gren's syndrome","volume":"12","author":"Soret","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102578_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102578_bib68","doi-asserted-by":"crossref","unstructured":"Bucci LHM, Boeltz S, Noethling D, Rothe T, Raimondo M, Tur C, Wirsching A, Wacker J, Bozec A, Schett G, Grieshaber-Bouyer R : BCMA-Targeted Bispecific T Cell-Engager Therapy of Autoimmune Disease [abstract]; Arthritis Rheumatol 2024; 76 (suppl 9).","DOI":"10.1038\/s41591-024-02964-1"},{"key":"10.1016\/j.coi.2025.102578_bib69","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1517\/14712598.2015.1064894","article-title":"Advances in salivary gland gene therapy - oral and systemic implications","volume":"15","author":"Baum","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coi.2025.102578_bib70","article-title":"Correction of Sj\u00f6gren\u2019s syndrome fluid secretion deficits in salivary gland acinar cells by aquaporin-1 gene transfer [abstract]","volume":"72","author":"Perez","year":"2020","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102578_bib71","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2013.278448","article-title":"Autoantibodies present before symptom onset in primary Sj\u00f6gren syndrome","volume":"310","author":"Jonsson","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.coi.2025.102578_bib72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/art.41091","article-title":"Timing of elevations of autoantibody isotypes prior to diagnosis of rheumatoid arthritis","volume":"72","author":"Kelmenson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102578_bib73","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102578_bib74","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102578_bib75","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/dc11-0523","article-title":"Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial","volume":"34","author":"Vehik","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.coi.2025.102578_bib76","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/1529-0131(200005)43:5<1054::AID-ANR14>3.0.CO;2-W","article-title":"Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen","volume":"43","author":"McKown","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102578_bib77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.0105-2896.2005.00280.x","article-title":"Oral tolerance","volume":"206","author":"Faria","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2025.102578_bib78","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.7680493","article-title":"Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis","volume":"259","author":"Weiner","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102578_bib79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2011.10.002","article-title":"HLA and Sj\u00f6gren's syndrome susceptibility. A meta-analysis of worldwide studies","volume":"11","author":"Cruz-Tapias","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102578_bib80","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39127","article-title":"Familial risk of Sj\u00f6gren's syndrome and co-aggregation of autoimmune diseases in affected families: a nationwide population study","volume":"67","author":"Kuo","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:08:07Z","timestamp":1779084487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":80,"alternative-id":["S0952791525000548"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102578","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we cure Sjogren\u2019s disease? Unmet needs and raising questions in the era of Precision medicine","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102578"}}